

Supplementary Table 1: Indications of common immunosuppressant drugs

	human	NHP	mouse	rat	dog	pig	sheep	
Glucocorticoids (GCs)	Dexamethasone® (DM)	solid organ Tx ¹	experimental sepsis model ²	neural graft ³	improvement of myocardial vitality after cardioplegia (for 6 h under hypothermia) ⁴			
	Prednisolone® (P)	acute rejection after homograft Tx ⁵ decrease of reperfusion damage after liver Tx ⁶ renal allografts ⁷	allogenic skin Tx ⁸	inhibition of corneal transplant rejection ⁹ decrease of reperfusion damage after orthotopic lung Tx ¹⁰ orthotopic liver Tx ¹¹ hind limb allograft Tx ¹²	allogenic renal Tx ¹³	allogenic skin Tx ^{14,15} bronchial allograft Tx ¹⁶ small bowel Tx ¹⁷ lung Tx ¹⁸	heart Tx ¹⁹	
Cytostatic drugs	Azathioprine (Az)	kidney Tx ²⁰ liver Tx ²⁰ heart Tx ²⁰			bone graft ²¹	islet Tx ²²		
	Cyclophosphamide® (CY)	chemotherapy ²³ rheumatoid arthritis ²³	bone marrow Tx ²⁴	immunosuppression to develop a tolerance of ovine erythrocytes ^{25,26}	pancreas Tx combined with stem cell (bone marrow) Tx ²⁷	xenogenic Tx of erythrocytes ²⁸	immunosuppression ²⁹	depression of hematopoiesis ³⁰
	Methotrexate® (MTX)	autoimmune hepatitis type 1 ³¹ corneal ulcer, Mooren's ulcer ³²		Pompe disease ³³	arthritis ³⁴ radiculopathy ³⁵	bone marrow cell Tx ³⁶	medulloblastoma ³⁷	squamous cell carcinoma ³⁸
Mycophenolate mofetil® (MMF)	rheumatoid arthritis ³⁹ autoimmune hepatitis type 1 ⁴⁰		heterotopic heart Tx ⁴¹	reduction of antibody production against ovine erythrocytes ⁴² intracerebral Tx of porcine nervous tissue ⁴³	allogenic renal Tx ⁴⁴	allogenic pancreatic islets Tx ⁴⁵ allogenic bowel Tx ⁴⁶ treatment of reperfusion damage after renal Tx ⁴⁷	allogenic uterus Tx ⁴⁸	
Immunophilin drugs	Ciclosporin A® (CsA)	stem cell alloTx (bone marrow) ⁴⁹	skin allograft Tx (survival time: 13.1±1.6 days) ⁵⁰	embryonal stem cell Tx into the spine ⁵¹ heart Tx ⁵²	allogenic renal Tx ⁵³	liver Tx ^{54,55} renal Tx ^{54,55} immunosuppressive therapy: 400-800 ng CsA×mL ⁻¹ trough blood level ⁵⁶	xenogeneic skin Tx ⁵⁷	
	Tacrolimus® (Tcr)	refractory ulcerative colitis ⁵⁸	renal allograft Tx in vervet monkeys ⁵⁹ renal allograft Tx in cynomolgus monkeys ⁶⁰	renal ischemic reperfusion ⁶¹	renal Tx ⁶²	heart allograft Tx ⁶³ partial liver Tx ⁶⁴ renal allograft Tx ⁶⁵	uterus allograft Tx ⁴⁸	
	Rapamycin® (Rpm)	renal allografts ⁶⁶	skin allograft Tx ⁶⁷	renal allograft ⁶⁸	bone marrow Tx ⁶⁹	bronchial xenograft Tx ⁷⁰		
	Everolimus (Ev)	renal and cardiac Tx ⁷¹		heart alloTx ⁷²			bronchial xenoTx ⁷³	
Cell therapy	Regulatory T cells (T _{reg})		syngenic bone marrow Tx ⁷⁴	renal allograft Tx ⁷⁵	bone marrow Tx ⁷⁶	cardiac allograft Tx ⁷⁷		
	Mesenchymal stem cells (MSCs)	therapy GvHD ⁷⁸ refractory GvHD ⁷⁹	GvHD-like model (Fricke, 2014, unpubl. data)	stroke model (occlusion and reperfusion) ⁸⁰	failed GvHD prophylaxis in bone marrow Tx ⁸¹	femoral artery Tx ⁸²	neuroprotection in hypoxic-ischemic encephalopathy ⁸³	
Antibodies	Anti-lymphocyte globulin® (ALG)	GvHD prophylaxis after bone marrow Tx ⁸⁴ renal allograft Tx ⁸⁵	skin Tx in rhesus monkeys ⁸⁶	islet Tx ⁸⁷	small bowel allograft Tx ⁸⁸	renal allograft and bone marrow Tx ⁸⁹		
	Anti-thymocyte globulin® (ATG)	renal Tx ⁹⁰	pig to baboon bone marrow xenoTx ⁹¹	skin Tx ⁹²	renal allograft Tx ⁹³	immunosuppression in a viral infection model ⁹⁴	islet allograft Tx ⁹⁵	uterus allograft Tx ⁴⁸
	Rituximab® (RTB)	apoptosis induction in lymphoma cells ⁹⁶	apoptosis induction in lymphoma cells in cynomolgus monkeys ⁹⁷ cardiac xenoTx (pig to baboon) ⁹⁸	bioavailability experiments ⁹⁹				
CD28/B7	renal transplantation ¹⁰⁰							

References

- 1 van Sandwijk, M S, Bemelman FJ, Ten Berge, I J M. Immunosuppressive drugs after solid organ transplantation. *Neth J Med* 2013; **71**: 281–9.
- 2 Aytac HO, Iskit AB, Sayek I. Dexamethasone effects on vascular flow and organ injury in septic mice. *J Surg Res* 2014; **188**: 496–502.
- 3 Feng Y, Zengmin T, Shuang L, Quanjun Z, Yaming W, Qiuxing H. Local effects of dexamethasone on immune reaction in neural transplantation. *Transpl Immunol* 2007; **18**: 126–9.
- 4 Miyamoto H, Sunamori M, Yoshida T, Suzuki A. The effect of betamethasone on myocardial viability during cold cardioplegia in canine donor heart preservation. *Surg Today* 1994; **24**: 449–55.
- 5 Melby JC. Clinical pharmacology of systemic corticosteroids. *Annu Rev Pharmacol Toxicol* 1977; **17**: 511–27.
- 6 Orci LA, Toso C, Mentha G, Morel P, Majno PE. Systematic review and meta-analysis of the effect of perioperative steroids on ischaemia-reperfusion injury and surgical stress response in patients undergoing liver resection. *Br J Surg* 2013; **100**: 600–9.
- 7 Muhetaer G, Takeuchi H, Unezaki S, Kawachi S, Iwamoto H, Nakamura Y et al. Clinical Significance of Peripheral Blood Lymphocyte Sensitivity to Glucocorticoids for the Differentiation of High-risk Patients With Decreased Allograft Function After Glucocorticoid Withdrawal in Renal Transplantation. *Clin Ther* 2014; **36**: 1264–72.
- 8 Nishihira T, Ishii H, Kasai M, Tachibana T. Prolonged survival time of allogeneic skin grafts in host pretreated with somatic cell hybrids and prednisolone. *Tohoku J Exp Med* 1979; **129**: 71–4.
- 9 Kagaya F, Usui T, Kamiya K, Ishii Y, Tanaka S, Amano S et al. Intraocular dexamethasone delivery system for corneal transplantation in an animal model. *Cornea* 2002; **21**: 200–2.
- 10 Paulus P, Holfeld J, Urbschat A, Mutlak H, Ockelmann PA, Tacke S et al. Prednisolone as preservation additive prevents from ischemia reperfusion injury in a rat model of orthotopic lung transplantation. *PLoS ONE* 2013; **8**: e73298.
- 11 Chimalakonda AP, Mehvar R. Effects of methylprednisolone and its liver-targeted dextran prodrug on ischemia-reperfusion injury in a rat liver transplantation model. *Pharm Res* 2007; **24**: 2231–8.
- 12 Pan H, Wang L, Zhang X, Zhang G, Mai H, Han Y et al. Rapamycin, mycophenolate mofetil, methylprednisolone, and cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-based conditioning regimen to induce partial tolerance to hind limb allografts without cytoreductive conditioning. *Transplant Proc* 2008; **40**: 1714–21.
- 13 Haishima A, Kawakami Y, Mizuno S, Kageyama T, Muto M, Suzuki T et al. Acute vascular and interstitial rejection following renal allograft transplantation in dogs. *J Vet Med Sci* 2002; **64**: 1137–40.
- 14 Ustüner ET, Zdichavsky M, Ren X, Edelstein J, Maldonado C, Ray M et al. Long-term composite tissue allograft survival in a porcine model with cyclosporine/mycophenolate mofetil therapy. *Transplantation* 1998; **66**: 1581–7.
- 15 Zdichavsky M, Jones JW, Ustuner ET, Ren X, Edelstein J, Maldonado C et al. Scoring of skin rejection in a swine composite tissue allograft model. *J Surg Res* 1999; **85**: 1–8.
- 16 Salminen US, Uusitalo M, Ikonen T, Taskinen E, Morris RE, Harjula AL. Effect of immunosuppression on obliterative lesions in a heterotopic large-animal bronchial allograft model. *Transplant Proc* 1997; **29**: 3155–6.
- 17 Rossi G, Gatti S, Reggiani P, Galmarini D, Privitera G, Velio P et al. Small bowel transplantation under oral immunosuppression: experimental study in the pig. *Transplant Proc* 1997; **29**: 1816–8.
- 18 Inui K, Schäfers HJ, Aoki M, Wada H, Becker V, Ongsiek B et al. Effect of methylprednisolone and prostacyclin on bronchial perfusion in lung transplantation. *Ann Thorac Surg* 1993; **55**: 464–9.
- 19 Segel LD, Follette DM, Castellanos LM, Hayes R, Baker JM, Smolens IV. Steroid pretreatment improves graft recovery in a sheep orthotopic heart transplantation model. *J Surg Res* 1997; **16**: 371–80.
- 20 BC Transplant agency of the Provincial Health Services Authority (PHSA). Clinical Guidelines for Transplant Medications, 2015 cited 2016 Apr 24]. Available from: URL:<http://www.transplant.bc.ca/health-professionals/pharmacy>.
- 21 Goldberg VM, Powell A, Shaffer JW, Zika J, Bos GD, Heiple KG. Bone grafting: role of histocompatibility in transplantation. *J Orthop Res* 1985; **3**: 389–404.
- 22 Sutherland DE, Steffes MW, Bauer GE, McManus D, Noe BD, Najarian JS. Isolation of human and porcine islets of Langerhans and islet transplantation in pigs. *J Surg Res* 1974; **16**: 102–11.
- 23 Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. *J Am Acad Dermatol* 1984; **11**: 1115–26.
- 24 Storb R, Buckner CD, Dillingham LA, Thomas ED. Cyclophosphamide regimens in rhesus monkey with and without marrow infusion. *Cancer Res* 1970; **30**: 2195–203.
- 25 Hall JM, Ohno S, Pribnow JF. The effect of cyclophosphamide on an ocular immune response. I. Primary response. *Clin Exp Immunol* 1977; **30**: 309–16.
- 26 Many A, Schwartz RS. On the mechanism of immunological tolerance in cyclophosphamide-treated mice. *Clin Exp Immunol* 1970; **6**: 87–99.

- 27 Luo Q, Lu M, Luo L, Fu Y, Fu J, Huang Z. [Immune tolerance induced by bone marrow cell transplantation combined with use of cyclophosphamide in diabetic rats with pancreatic transplantation]. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2011; **42**: 106-8, 124.
- 28 Putnam CW, Halgrimson CG, Groth CG, Kashiwagi N, Porter KA, Starzl TE. Immunosuppression with cyclophosphamide in the dog. *Clin Exp Immunol* 1975; **22**: 323-9.
- 29 Han J, Liu YL, Fan W, Chao J, Hou YQ, Yin YL et al. Dietary L-arginine supplementation alleviates immunosuppression induced by cyclophosphamide in weaned pigs. *Amino Acids* 2009; **37**: 643-51.
- 30 B. Hofírek, J. Drábek. Cytostatic effect of cyclophosphamide on bone marrow in sheep. *Acta Vet Brno* 1980; 217-22.
- 31 Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. *J Hepatol* 1998; **29**: 990-3.
- 32 Ashar JN, Mathur A, Sangwan VS. Immunosuppression for Mooren's ulcer: evaluation of the step-ladder approach--topical, oral and intravenous immunosuppressive agents. *Br J Ophthalmol* 2013; **97**: 1391-4.
- 33 Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. *Clin Exp Immunol* 2008; **152**: 138-46.
- 34 Suzuki Y, Nakagawa M, Masuda C, Ide M, Uehara R, Ichikawa Y et al. Short-term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis. *J Rheumatol* 1997; **24**: 1890-5.
- 35 Hashizume H, Rutkowski MD, Weinstein JN, DeLeo JA. Central administration of methotrexate reduces mechanical allodynia in an animal model of radiculopathy/sciatica. *Pain* 2000; **87**: 159-69.
- 36 Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. *Blood* 1997; **89**: 3048-54.
- 37 Sandberg DI, Solano J, Petito CK, Mian A, Mou C, Koru-Sengul T et al. Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model. *J Neurooncol* 2010; **100**: 397-406.
- 38 Harker GJ, Stephens FO, Wass J, Zbroja RA, Chick BF, Grace J. A preliminary report on the suitability of sheep epidermal squamous cell carcinoma as a solid tumor model in the evaluation of intra-arterial methotrexate administration. *J Surg Oncol* 1986; **32**: 65-72.
- 39 Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. *Clin Exp Rheumatol* 1993; **11 Suppl 8**: S117-9.
- 40 Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. *J Hepatol* 2009; **51**: 156-60.
- 41 Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. *Transplant Proc* 1990; **22**: 1659-62.
- 42 Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. *Transplant Proc* 1991; **23**: 10-4.
- 43 Wennberg L, Czech KA, Larsson LC, Mirza B, Bennet W, Song Z et al. Effects of immunosuppressive treatment on host responses against intracerebral porcine neural tissue xenografts in rats. *Transplantation* 2001; **71**: 1797-806.
- 44 Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443--a new, potent immunosuppressive agent. *Transplantation* 1991; **51**: 27-31.
- 45 Echeverri GJ, McGrath K, Bottino R, Hara H, Dons EM, van der Windt, D J et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. *Am J Transplant* 2009; **9**: 2485-96.
- 46 Gruessner, Rainer W G, Levay-Young BK, Nakhleh RE, Shearer JD, Dunning M, Nelson CM et al. Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. *Transplantation* 2004; **77**: 1500-6.
- 47 Treska V, Molacek J, Kobl J, Racek J, Trefil L, Hes O. Ischemic training and immunosuppressive agents reduce the intensity of ischemic reperfusion injury after kidney transplantation. *Exp Clin Transplant* 2006; **4**: 439-44.
- 48 Wei L, Xue T, Yang H, Zhao G, Zhang G, Lu Z et al. Modified uterine allotransplantation and immunosuppression procedure in the sheep model. *PLoS ONE* 2013; **8**: e81300.
- 49 Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. *Bone Marrow Transplant* 1997; **19**: 759-64.
- 50 Lagodzinski Z, Górski A, Wasik M. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. *Immunology* 1990; **71**: 148-50.
- 51 McDonald JW, Liu XZ, Qu Y, Liu S, Mickey SK, Turetsky D et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. *Nat Med* 1999; **5**: 1410-2.

- 52 Bolling SF, Lin H, Annesley TM, Boyd JA, Gallagher KP, Levy RJ. Local cyclosporine immunotherapy of heart transplants in rats enhances survival. *J Surg Res* 1991; **10**: 577–83.
- 53 Archer TM, Boothe DM, Langston VC, Fellman CL, Lunsford KV, Mackin AJ. Oral cyclosporine treatment in dogs: a review of the literature. *J Vet Intern Med* 2014; **28**: 1–20.
- 54 Rosengard BR, Ojikutu CA, Guzzetta PC, Smith CV, Sundt TM, Nakajima K et al. Induction of specific tolerance to class I-disparate renal allografts in miniature swine with cyclosporine. *Transplantation* 1992; **54**: 490–7.
- 55 Bom-van Noorloos, A A, Visser JJ, Drexhage HA, Meijer S, Hoitsma HF. Cyclosporin A in orthotopic porcine liver transplantation. Long-term survival after short-term treatment. *Eur Surg Res* 1984; **16**: 329–35.
- 56 Pan H, Gazarian A, Buff S, Solla F, Gagnieu M, Leveneur O et al. Oral cyclosporine A in neonatal swines for transplantation studies. *Immunopharmacol Immunotoxicol* 2014; **100**: 1–7.
- 57 Rose AH, Ilett KF, O'Donoghue HL, Hackett LP, Penhale WJ, Manning LS et al. Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. *Vet Immunol Immunopathol* 2001; **81**: 23–36.
- 58 Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. *Gut* 2006; **55**: 1255–62.
- 59 Chen H, Peng J, Luo H, Loubeau M, Wan X, Xu D et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. *Transplantation* 2000; **69**: 1555–61.
- 60 Song L, Ma A, Dun H, Hu Y, Zeng L, Bai J et al. Effects of ASKP1240 Combined With Tacrolimus or Mycophenolate Mofetil on Renal Allograft Survival in Cynomolgus Monkeys. *Transplantation* 2014; **98**: 267–76.
- 61 Cavalli RC, Tambara Filho R, Gomes, Regina de Paula Xavier, Veronez, Djanira Aparecida da Luz, Slongo J, Fraga Rd. Analysis of the histology of the scar bladder and biochemical parameters of rats with a solitary kidney undergoing immunosuppression with tacrolimus. *Acta Cir Bras* 2014; **29**: 508–14.
- 62 Suzuki T, Jin MB, Shimamura T, Yamashita K, Taniguchi M, Nomura M et al. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments. *Transpl Int* 2004; **17**: 574–84.
- 63 Madariaga ML, Michel SG, Tasaki M, Villani V, La Muraglia, G M, Sihag S et al. Induction of cardiac allograft tolerance across a full MHC barrier in miniature swine by donor kidney cotransplantation. *Am J Transplant* 2013; **13**: 2558–66.
- 64 Kelly DM, Zhu X, Shiba H, Irefin S, Trenti L, Cocieru A et al. Adenosine restores the hepatic artery buffer response and improves survival in a porcine model of small-for-size syndrome. *Liver Transpl* 2009; **15**: 1448–57.
- 65 Griesemer AD, Lamattina JC, Okumi M, Etter JD, Shimizu A, Sachs DH et al. Linked suppression across an MHC-mismatched barrier in a miniature swine kidney transplantation model. *J Immunol* 2008; **181**: 4027–36.
- 66 MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. *Transplantation* 2001; **71**: 271–80.
- 67 Pilon CB, Petillon S, Naserian S, Martin GH, Badoual C, Lang P et al. Administration of Low Doses of IL-2 Combined to Rapamycin Promotes Allogeneic Skin Graft Survival in Mice. *Am J Transplant* 2014; **14**: 2874–82.
- 68 Ko HT, Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD et al. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. *Nephrol Dial Transplant* 2013; **28**: 327–36.
- 69 Hogan WJ, Little M, Zellmer E, Friedetzky A, Diaconescu R, Gisburne S et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. *Biol Blood Marrow Transplant* 2003; **9**: 489–95.
- 70 Salminen US, Maasilta PK, Taskinen EI, Harjula AL. Obliterative lesions in a heterotopic bronchial xenograft model--a preliminary study. *Transplantation* 2000; **70**: 48–50.
- 71 Chapman TM, Perry CM. Everolimus. *Drugs* 2004; **64**: 861-72; discussion 873-4.
- 72 Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. *Transplantation* 2003; **75**: 1710–7.
- 73 Maasilta PK, Vainikka, Tiina L S, Alho HS, Salminen U. Immune cells in a heterotopic lamb-to-pig bronchial xenograft model. *Transpl Int* 2005; **18**: 1100–8.
- 74 Fricke S, Rothe K, Hilger N, Ackermann M, Oelkrug C, Fricke C et al. Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure. *Cytometry A* 2012; **81**: 476–88.
- 75 Yu X, Huang C, Song B, Xiao Y, Fang M, Feng J et al. CD4+CD25+ regulatory T cells-derived exosomes prolonged kidney allograft survival in a rat model. *Cell Immunol* 2013; **285**: 62–8.

- 76 Weiden PL, Storb R, Tsoi MS, Graham TC, Lerner KG, Thomas ED. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. *J Immunol* 1976; **116**: 1212–9.
- 77 Mezrich JD, Kesselheim JA, Johnston DR, Yamada K, Sachs DH, Madsen JC. The role of regulatory cells in miniature swine rendered tolerant to cardiac allografts by donor kidney cotransplantation. *Am J Transplant* 2003; **3**: 1107–15.
- 78 Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp Hematol* 2003; **31**: 890–6.
- 79 Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. *Bone Marrow Transplant* 2010; **45**: 1732–40.
- 80 Fukuda Y, Horie N, Satoh K, Yamaguchi S, Morofuji Y, Hiu T et al. Intra-Arterial Transplantation of Low-Dose Stem Cells Provides Functional Recovery Without Adverse Effects After Stroke. *Cell Mol Neurobiol* 2014.
- 81 Mielcarek M, Storb R, Georges GE, Golubev L, Nikitine A, Hwang B et al. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation. *Biol Blood Marrow Transplant* 2011; **17**: 214–25.
- 82 Jui H, Lin C, Hsu W, Liu Y, Hsu R, Chiang B et al. Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon- γ , and indoleamine 2,3-dioxygenase. *Cell transplantation* 2012; **21**: 971–84.
- 83 Jellema RK, Wolfs, Tim G A M, Lima Passos V, Zwanenburg A, Ophelders, Daan R M G, Kuypers E et al. Mesenchymal stem cells induce T-cell tolerance and protect the preterm brain after global hypoxia-ischemia. *PLoS ONE* 2013; **8**: e73031.
- 84 Wolschke C, Zabelina T, Ayuk F, Alchalby H, Berger J, Klyuchnikov E et al. Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation. *Bone Marrow Transplant* 2014; **49**: 126–30.
- 85 Ringdén O, Quadracci LJ, Groth CG. The effects of anti-lymphocyte globulin on lymphocyte subpopulations in recipients of kidney allografts. *Scand J Urol Nephrol Suppl* 1977: 86–9.
- 86 Balner H, Yron I, Dersjant H, Zaalberg O, Betel I. ALG treatment of Rhesus monkeys. Attempts to reduce complications by the induction of tolerance. *Transplantation* 1970; **10**: 416–24.
- 87 Gotoh M, Fukuzaki T, Monden M, Dono K, Kanai T, Yagita H et al. A potential immunosuppressive effect of anti-lymphocyte function-associated antigen-1 monoclonal antibody on islet transplantation. *Transplantation* 1994; **57**: 123–6.
- 88 Sun S, Greenstein SM, Schechner RS, Tellis VA. Prolonged small bowel allograft survival following repeated intrathymic injections of donor splenocytes and peripheral anti-lymphocyte treatment. *Transplant Proc* 1999; **31**: 588–9.
- 89 Hartner WC, Markees TG, De Fazio, S R, Shaffer D, Van Der Werf, W J, Gilchrist B et al. Effect of early administration of donor bone marrow cells on renal allograft survival in dogs treated with antilymphocyte serum and cyclosporine. *Transplantation* 1995; **59**: 131–4.
- 90 Yang J, Wang J, Men T, Zhang X, Li X, Shen B et al. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience. *Ann Transplant* 2014; **19**: 277–82.
- 91 Griesemer A, Liang F, Hirakata A, Hirsh E, Lo D, Okumi M et al. Occurrence of specific humoral non-responsiveness to swine antigens following administration of GalT-KO bone marrow to baboons. *Xenotransplantation* 2010; **17**: 300–12.
- 92 D'Addio F, Boenisch O, Magee CN, Yeung MY, Yuan X, Mfarrej B et al. Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model. *PLoS ONE* 2013; **8**: e53797.
- 93 Valdez-Ortiz R, Bestard O, Llaudó I, Franquesa M, Cerezo G, Torras J et al. Induction of suppressive allogeneic regulatory T cells via rabbit antithymocyte polyclonal globulin during homeostatic proliferation in rat kidney transplantation. *Transpl Int* 2014.
- 94 Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. *Mol Ther* 2007; **15**: 1160–6.
- 95 Liu X, Hering BJ, Mellert J, Brandhorst D, Brandhorst H, Federlin K et al. Prevention of primary nonfunction after porcine islet allotransplantation. *Transplant Proc* 1997; **29**: 2071–2.
- 96 Kneba M. Antikörpertherapie in der Hämatologie und Onkologie. Bremen: Uni-Med, 2001.
- 97 Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. *Blood* 1994; **83**: 435–45.
- 98 McGregor, Christopher G A, Davies WR, Oi K, Teotia SS, Schirmer JM, Risdahl JM et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. *J Thorac Cardiovasc Surg* 2005; **130**: 844–51.
- 99 Kagan L, Zhao J, Mager DE. Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. *Pharm Res* 2014; **31**: 3265–73.

